We witnessed a truly historic edition of ECTRIMS last week in Copenhagen. Here are my personal top 5 highlights 🔁💡💊☀️🌎
1️⃣ 🔁 Updated McDonald Criteria:
Looking at the number of people in the lecture hall, the revision of the McDonald Diagnostic Criteria was everyone’s #1 highlight. Key changes include recognizing RIS as MS in specific situations and the growing role of #MRI findings such as the central vein sign and paramagnetic rim lesions.
2️⃣ 💡Promising news on BTKi Tolebrutinib:
The HERCULES trial showed promising results for SPMS, demonstrating a positive effect on disability progression. The GEMINI trials in RRMS showed no effect on relapses, even though a positive impact on disability progression was shown.
3️⃣ 💊 MS-STAT2 trial results:
Unfortunately, the MS-STAT2 trial, involving over 900 participants, found that Simvastatin did not slow progression in secondary progressive MS.
4️⃣ ☀️ Vitamin D trial findings:
The D-Lay MS trial, the largest therapeutic study of vitamin D ever in MS, showed that high-dose vitamin D supplementation significantly reduced disease activity in people with #MS.
5️⃣ 🌎 Collaborations all around:
More than ever, we are witnessing remarkable large-scale collaborations and initiatives dedicated to improving the lives of people with MS.
➡️ From the groundbreaking CLAIMS initiative (Giancarlo Comi, Friedemann Paul, Dana Horáková, patrick vermersch, Carsten Lucas, Tjalf Ziemssen et al) to impactful programs like the Multiple Sclerosis Association of America (MSAA) MRI Access Program, which provides vital support for individuals with limited access to care, the sense of global teamwork is truly inspiring.
➡️ It’s incredible to see world-class experts from diverse regions and clinical contexts, such as Klaus Schmierer, Stephen Krieger, and Augusto Miravalle, come together to address specific challenges faced by those with MS, like communication around diagnosis.
➡️ The most meaningful impact for people with #multiplesclerosis is made by collaborating across stakeholders, it was so nice to discuss care and outcomes with the National MS Society, Roche, Merck Life Science, Novartis, Sanofi, Alexion Pharmaceuticals, Inc., Amgen, Sandoz, TG Therapeutics, Inc., Biogen, Bristol Myers Squibb, Neuraxpharm.
The MS community feels more connected and collaborative than ever before and icometrix is proud to be part of so many exciting initiatives, studies, and collaborations that will improve the quality of life of people living with MS.
Thank you, #ECTRIMS2024, for hosting such an inspiring event.
#MultipleSclerosis #Neurology #icobrain #icompanion #AI